Genetic Testing for Family Members of Children with ASD
Parents and siblings of a child diagnosed with autism spectrum disorder do not routinely require genetic testing themselves; instead, genetic counseling should be offered to discuss recurrence risks and family planning, with testing reserved for specific clinical scenarios.
Primary Recommendation for the Affected Child
The affected child with ASD should undergo genetic evaluation, not the family members. A genetic consultation should be offered to all persons/families with ASDs 1. The 2013 ACMG guidelines establish that genetic testing should be discussed with all patients and families with ASDs, as diagnostic yield has increased from 6-10% to 30-40% 1. More recent evidence from 2020 suggests considering immediate referral to clinical genetics to guide the genetic evaluation 2.
Genetic Counseling for Family Members (Not Testing)
The key intervention for parents and siblings is genetic counseling, not genetic testing 1. Upon completion of the affected child's clinical genetics evaluation, genetic counseling should be provided to families to discuss:
Recurrence Risk Data for Siblings:
- Full siblings: 3-10% recurrence risk (though newer studies suggest this may be higher) 1
- Modified by sex of affected child:
- 7% risk if the affected child is female
- 4% risk if the affected child is male
- If two or more children already have ASD: at least 30% recurrence risk 1
When Family Member Testing May Be Indicated
Genetic testing of parents or siblings should be considered only in specific circumstances:
For Parents:
- When a pathogenic variant is identified in the affected child - parental testing helps determine if the variant is de novo or inherited, which significantly impacts recurrence risk counseling
- If family history suggests X-linked disorder - consider testing for X-inactivation skewing in the mother 2
- For family planning purposes - after identification of a causative variant in the affected child
For Siblings:
- If siblings show developmental concerns or ASD features - they should undergo their own independent clinical evaluation and genetic testing as indicated
- Not for predictive testing in asymptomatic siblings - current guidelines do not recommend testing unaffected siblings to predict future ASD risk
Recommended Testing Approach for the Affected Child
The tiered approach for the affected child includes 1, 2:
First-Tier Testing:
- Chromosomal microarray (CMA) - recommended for all patients
- Fragile X testing - particularly for males, or if family history suggests Fragile X syndrome
- Three-generation family history with pedigree analysis
Second-Tier Testing (if first-tier unrevealing):
- MECP2 sequencing - for all females; for males if phenotype suggestive
- PTEN testing - if head circumference >2.5 SD above mean
- Exome sequencing (ES) or whole genome sequencing
- Metabolic/mitochondrial testing - if clinically indicated
Important Clinical Pitfalls
Common misconception: Families often believe all members need testing when one child is diagnosed. The evidence clearly shows that genetic counseling, not routine testing of unaffected family members, is the standard of care 1.
Barrier to care: Only about one-third of parents report receiving genetic testing recommendations from providers 3, representing a significant gap in guideline implementation. Healthcare providers must proactively discuss genetic evaluation.
Timing consideration: The clinical genetic evaluation must be customized to the clinical situation, and periodic reevaluations should be considered for patients in whom a definitive etiology is not initially discovered 1.
Role of the Primary Care Provider
The primary care physician and clinical geneticist should partner in ordering, scheduling, and coordinating recommended diagnostic tests 1. The referring professional should discuss expectations and possible outcomes before making the referral, as this significantly impacts whether families pursue testing 3.